作者: Indicative 時(shí)間: 2025-3-21 21:24
Biosynthetic Enzymes of Membrane Glycerophospholipid Diversity as Therapeutic Targets for Drug Devecorporate fatty chains into lysophospholipids to affect the fatty acid composition of membrane glycerophospholipids. Lysophosphatidic acid acyltransferases (LPAATs) of the 1-acylglycerol-3-phosphate .-acyltransferase (AGPAT) family incorporate fatty chains into phosphatidic acid during the . glycero作者: 種屬關(guān)系 時(shí)間: 2025-3-22 04:08
Druggable Prostanoid Pathway, (AA). Protanoids control numerous physiological and pathological processes. Cyclooxygenase (COX) is a rate-limiting enzyme involved in the conversion of AA into prostanoids. There are two COX isozymes: the constitutive COX-1 and the inducible COX-2. COX-1 and COX-2 have similar structures, catalyti作者: Gerontology 時(shí)間: 2025-3-22 08:21
Targeting Leukotrienes as a Therapeutic Strategy to Prevent Comorbidities Associated with Metabolicto exerting potent proinflammatory effects. Therefore,?LTs are essential elements in the development and maintenance of different chronic diseases, such as asthma, arthritis, and atherosclerosis. Due to the pleiotropic effects of LTs in the pathogenesis of inflammatory diseases, studies are needed t作者: 笨拙處理 時(shí)間: 2025-3-22 10:37 作者: Ruptured-Disk 時(shí)間: 2025-3-22 15:01 作者: Ruptured-Disk 時(shí)間: 2025-3-22 18:36
Druggable Lysophospholipid Signaling Pathways,lmost every major organ system. In this review we discuss LPA signaling pathways as emerging drug targets for multiple conditions relevant to human health and disease. LPA signals through the six G protein-coupled receptors LPA., and several of these receptors along with the LPA-producing enzyme inc作者: 滔滔不絕的人 時(shí)間: 2025-3-22 22:15 作者: 陪審團(tuán) 時(shí)間: 2025-3-23 03:55 作者: Limerick 時(shí)間: 2025-3-23 06:05 作者: 真繁榮 時(shí)間: 2025-3-23 11:28 作者: expansive 時(shí)間: 2025-3-23 16:08
0065-2598 overing drugs in lipid signaling pathways.Written by the nex.Lipids are responsible not just for constituting cellular membrane but also for storing energy, transducing signaling, and modifying proteins. Bioactive lipids, or lipid mediators, transduce signaling as intracellular messenger like phosph作者: 出處 時(shí)間: 2025-3-23 18:41 作者: hermetic 時(shí)間: 2025-3-24 00:20 作者: 千篇一律 時(shí)間: 2025-3-24 04:13
Introduction to Work Life 2000 Workshopsew examines current knowledge of the endocannabinoid system including metabolic enzymes involved in biosynthesis and degradation and their receptors, and evaluates potential druggable targets for therapeutic intervention.作者: 缺乏 時(shí)間: 2025-3-24 10:18
Druggable Targets in Endocannabinoid Signaling,ew examines current knowledge of the endocannabinoid system including metabolic enzymes involved in biosynthesis and degradation and their receptors, and evaluates potential druggable targets for therapeutic intervention.作者: Compass 時(shí)間: 2025-3-24 13:44
Alexandra Weilenmann,Catrine Larssony of lipid research, many drugs targeting lipid receptors and enzymes that are responsible for lipid metabolism and function have been developed and applied to a variety of diseases. For example, non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed medications for fever, pain, and 作者: 離開 時(shí)間: 2025-3-24 17:32 作者: 樸素 時(shí)間: 2025-3-24 21:41 作者: 瑣碎 時(shí)間: 2025-3-25 03:08 作者: 打折 時(shí)間: 2025-3-25 06:51 作者: Cardioversion 時(shí)間: 2025-3-25 10:48
Elizabeth F. Churchill,Nina Wakefordlecular family is primarily represented by the bioactive molecules ceramide, sphingosine, and sphingosine 1-phosphate (S1P). The flux of sphingolipid metabolism at both the subcellular and extracellular levels provides multiple opportunities for pharmacological intervention. The caveat is that pertu作者: frenzy 時(shí)間: 2025-3-25 13:18 作者: 上下連貫 時(shí)間: 2025-3-25 16:17
Introduction to Work Life 2000 Workshopsr medicinal purposes continues to increase worldwide. Since the discovery of Δ.-tetrahydrocannabinol (THC) as the primary psychoactive component of cannabis over 50?years ago, substantial effort has been directed toward detection of endogenous mediators of cannabinoid activity. The discovery of anan作者: 自傳 時(shí)間: 2025-3-25 21:59
Conclusions From the First 12 Workshopsspects of how cells respond to their extracellular environment. In addition, they play critical roles in regulating membrane trafficking and lipid transport within the cell. The class I phosphoinositide kinases which generate the critical lipid signal PIP. are hyperactivated in numerous human pathol作者: 粗魯?shù)娜?nbsp; 時(shí)間: 2025-3-26 00:42 作者: 格言 時(shí)間: 2025-3-26 06:41
https://doi.org/10.1007/978-3-030-50621-6lipids; GPCR; drug discovery; disease; translational research作者: reflection 時(shí)間: 2025-3-26 09:10 作者: Verify 時(shí)間: 2025-3-26 15:40 作者: 狼群 時(shí)間: 2025-3-26 20:18 作者: 鐵塔等 時(shí)間: 2025-3-26 23:37 作者: 通便 時(shí)間: 2025-3-27 02:21 作者: 加花粗鄙人 時(shí)間: 2025-3-27 05:55
Alexandra Weilenmann,Catrine Larssongable Lipid Signaling Pathways” provides 9 outstanding reviews that summarize the currently available drugs that target lipid signaling pathways and also outlines future directions for drug discovery. The review chapters include lipid signaling pathways (prostanoids, leukotrienes, epoxy fatty acids,作者: 歹徒 時(shí)間: 2025-3-27 11:12
Studying the Use of Mobile Technologys. Essential physiological functions for LPLATs have been revealed in studies using gene-deficient mice, and important roles for several enzymes are also indicated in human diseases where their mutation or dysregulation causes or contributes to the pathological condition. Now several LPLATs are emer作者: Introduction 時(shí)間: 2025-3-27 16:26
Local Use and Sharing of Mobile Phonesfully designed to spare gastrointestinal toxicity, but predisposed patients to increased cardiovascular risks. These health complications from NSAIDs prompted interest in the downstream effectors of the COX enzymes as novel drug targets. This chapter describes various safety issues with tNSAIDs and 作者: 修剪過的樹籬 時(shí)間: 2025-3-27 19:40
Elizabeth F. Churchill,Nina Wakeford LT production and/or actions could represent an exciting new strategy to prevent or treat inflammatory diseases associated with metabolic disorders. This review is intended to shed light on the synthesis and actions of leukotrienes, the most common drugs used in clinical trials, and discuss the the作者: 協(xié)奏曲 時(shí)間: 2025-3-28 00:46 作者: decipher 時(shí)間: 2025-3-28 03:09
Studying the Use of Mobile Technologyal bioactive lysophospholipid (LPL) signaling molecules including lysophosphatidylserine and lysophosphatidylinositol, which represent the next wave of LPL druggable targets. An emerging theme in bioactive LPL signaling is that where the ligand is produced and how it is delivered to the cognate rece作者: 拋媚眼 時(shí)間: 2025-3-28 09:56
Conclusions From the First 12 Workshops-malarial and anti-cryptosporidium strategies. Therefore, the development of targeted isoform selective inhibitors for these enzymes are of paramount importance. The first generation of PI3K inhibitors have recently been clinically approved for a number of different cancers, highlighting their thera作者: 西瓜 時(shí)間: 2025-3-28 13:51
Wide Area GroupFlow System (WAGS),consolidates 46 lipid GPCRs and . several perplexing lipid GPCRs. Then, we further . the lipid GPCR-directed drugs from the literature and databases, which identified 24 clinical drugs targeting 16 unique lipid GPCRs available in the market and 44 drugs under evaluation in more than 100 clinical tri作者: Jubilation 時(shí)間: 2025-3-28 17:24 作者: GLIB 時(shí)間: 2025-3-28 21:45 作者: 抱狗不敢前 時(shí)間: 2025-3-29 00:25
Biosynthetic Enzymes of Membrane Glycerophospholipid Diversity as Therapeutic Targets for Drug Deves. Essential physiological functions for LPLATs have been revealed in studies using gene-deficient mice, and important roles for several enzymes are also indicated in human diseases where their mutation or dysregulation causes or contributes to the pathological condition. Now several LPLATs are emer作者: Bereavement 時(shí)間: 2025-3-29 03:05
Druggable Prostanoid Pathway,fully designed to spare gastrointestinal toxicity, but predisposed patients to increased cardiovascular risks. These health complications from NSAIDs prompted interest in the downstream effectors of the COX enzymes as novel drug targets. This chapter describes various safety issues with tNSAIDs and 作者: 神刊 時(shí)間: 2025-3-29 11:04
Targeting Leukotrienes as a Therapeutic Strategy to Prevent Comorbidities Associated with Metabolic LT production and/or actions could represent an exciting new strategy to prevent or treat inflammatory diseases associated with metabolic disorders. This review is intended to shed light on the synthesis and actions of leukotrienes, the most common drugs used in clinical trials, and discuss the the
